NICE has launched a new consultation on the use of CYP2C19 genotype testing to guide treatment after a stroke or transient ischaemic attack (TIA) or ‘mini-stroke’.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.